Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy ANGO Stock  Free ANGO Stock Alerts

AngioDynamics (ANGO) Financials

AngioDynamics logo
$8.63 -0.39 (-4.32%)
Closing price 05/6/2025 04:00 PM Eastern
Extended Trading
$8.90 +0.27 (+3.08%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for AngioDynamics

Annual Income Statements for AngioDynamics

This table shows AngioDynamics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 5/31/2022 5/31/2023 5/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -27 -52 -184
Consolidated Net Income / (Loss)		 -27 -52 -184
Net Income / (Loss) Continuing Operations		 -27 -52 -184
Total Pre-Tax Income 		-30 -54 -192
Total Operating Income		 -28 -51 -192
Total Gross Profit		 166 174 155
Total Revenue		 316 339 304
Operating Revenue		 316 339 304
Total Cost of Revenue		 150 165 149
Operating Cost of Revenue		 150 165 149
Total Operating Expenses		 194 225 347
Selling, General & Admin Expense		 38 40 41
Marketing Expense		 95 104 103
Research & Development Expense		 31 30 32
Amortization Expense		 19 19 13
Other Operating Expenses / (Income)		 1.21 2.32 0.43
Impairment Charge		 0.00 15 159
Restructuring Charge		 9.04 16 53
Other Special Charges / (Income)		 0.00 0.00 -54
Total Other Income / (Expense), net		 -1.48 -3.26 0.80
Interest Expense		 0.69 2.70 -1.61
Other Income / (Expense), net		 -0.79 -0.55 -0.82
Income Tax Expense		 -3.40 -2.00 -7.29
Basic Earnings per Share		 ($0.68) ($1.33) ($4.59)
Weighted Average Basic Shares Outstanding		 39.01M 39.48M 40.18M
Diluted Earnings per Share		 ($0.68) ($1.33) ($4.59)
Weighted Average Diluted Shares Outstanding		 39.01M 39.48M 40.18M
Weighted Average Basic & Diluted Shares Outstanding		 38.97M 39.67M 40.28M

Quarterly Income Statements for AngioDynamics

This table shows AngioDynamics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 8/31/2022 11/30/2022 2/28/2023 5/31/2023 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -8.49 -9.49 -21 46 -29 -188 -13 -13 -11 -4.41
Consolidated Net Income / (Loss)		 -13 -8.49 -9.49 -21 46 -29 -188 -13 -13 -11 -4.41
Net Income / (Loss) Continuing Operations		 -13 -8.49 -9.49 -21 46 -29 -188 -13 -13 -11 -4.41
Total Pre-Tax Income 		-14 -9.05 -9.66 -22 35 -13 -200 -14 -13 -11 -4.41
Total Operating Income		 -13 -8.12 -8.93 -21 35 -13 -200 -14 -13 -11 -9.97
Total Gross Profit		 42 45 41 46 40 40 36 39 37 40 39
Total Revenue		 82 85 81 91 79 79 75 71 67 73 72
Operating Revenue		 82 85 81 91 79 79 75 71 67 73 72
Total Cost of Revenue		 39 40 40 45 39 39 39 32 31 33 33
Operating Cost of Revenue		 39 40 40 45 39 39 39 32 31 33 33
Total Operating Expenses		 56 53 49 67 5.03 53 236 53 50 51 49
Selling, General & Admin Expense		 10 11 8.84 10 11 9.29 11 10 11 10 10
Marketing Expense		 27 26 25 26 27 25 25 25 26 26 26
Research & Development Expense		 8.33 6.84 6.85 7.86 7.94 8.66 8.19 6.72 6.29 6.43 6.91
Amortization Expense		 4.84 4.81 4.74 4.41 3.63 3.56 3.29 2.57 2.57 2.56 2.60
Other Operating Expenses / (Income)		 0.21 1.65 0.23 0.24 -0.13 0.22 0.11 0.23 0.08 0.16 0.04
Impairment Charge		 - - 0.00 - - - 159 - - - 0.00
Restructuring Charge		 5.58 3.06 3.37 3.62 3.21 6.19 35 8.42 4.31 5.87 3.29
Other Special Charges / (Income)		 0.00 0.00 0.00 - -48 0.00 -6.66 - 0.00 0.00 0.00
Total Other Income / (Expense), net		 -0.56 -0.94 -0.74 -1.03 -0.17 0.50 0.16 0.31 0.43 0.25 5.57
Interest & Investment Income		 - - - - 0.12 0.53 0.39 - 0.61 0.23 0.14
Other Income / (Expense), net		 -0.18 -0.25 0.00 -0.13 -0.29 -0.03 -0.24 -0.26 -0.17 0.01 5.43
Income Tax Expense		 -0.85 -0.57 -0.18 -0.40 -11 16 -12 -0.69 0.13 -0.11 -0.00
Basic Earnings per Share		 ($0.33) ($0.21) ($0.24) ($0.55) $1.15 ($0.72) ($4.67) ($0.35) ($0.31) ($0.26) ($0.11)
Weighted Average Basic Shares Outstanding		 39.30M 39.49M 39.51M 39.48M 39.84M 40.22M 40.23M 40.18M 40.65M 40.92M 40.85M
Diluted Earnings per Share		 ($0.33) ($0.21) ($0.24) ($0.55) $1.15 ($0.72) ($4.67) ($0.35) ($0.31) ($0.26) ($0.11)
Weighted Average Diluted Shares Outstanding		 39.30M 39.49M 39.51M 39.48M 39.97M 40.22M 40.23M 40.18M 40.65M 40.92M 40.85M
Weighted Average Basic & Diluted Shares Outstanding		 39.11M 39.13M 39.24M 39.67M 39.85M 39.86M 40.05M 40.28M 40.63M 40.47M 40.61M

Annual Cash Flow Statements for AngioDynamics

This table details how cash moves in and out of AngioDynamics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 5/31/2022 5/31/2023 5/31/2024
Net Change in Cash & Equivalents		 -19 16 31
Net Cash From Operating Activities		 -7.19 0.08 -28
Net Cash From Continuing Operating Activities		 -7.19 0.08 -28
Net Income / (Loss) Continuing Operations		 -27 -52 -184
Consolidated Net Income / (Loss)		 -27 -52 -184
Depreciation Expense		 29 31 28
Non-Cash Adjustments To Reconcile Net Income		 14 29 122
Changes in Operating Assets and Liabilities, net		 -24 -7.02 6.89
Net Cash From Investing Activities		 -19 -9.75 124
Net Cash From Continuing Investing Activities		 -19 -9.75 124
Purchase of Property, Plant & Equipment		 -4.30 -3.81 -2.52
Acquisitions		 -3.60 -0.54 -3.25
Divestitures		 0.00 0.00 135
Other Investing Activities, net		 -11 -5.39 -5.02
Net Cash From Financing Activities		 7.68 25 -64
Net Cash From Continuing Financing Activities		 7.68 25 -64
Repayment of Debt		 0.00 -46 -50
Issuance of Debt		 5.00 70 0.00
Other Financing Activities, net		 2.68 1.17 -14
Effect of Exchange Rate Changes		 -0.52 0.04 0.13
Cash Interest Paid		 0.56 2.58 0.00
Cash Income Taxes Paid		 0.33 0.34 0.46

Quarterly Cash Flow Statements for AngioDynamics

This table details how cash moves in and out of AngioDynamics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 8/31/2022 11/30/2022 2/28/2023 5/31/2023 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025
Net Change in Cash & Equivalents		 -4.26 5.29 0.25 15 13 3.31 18 -2.40 -21 -0.92 -9.33
Net Cash From Operating Activities		 -25 7.50 1.37 16 -26 5.27 -13 5.00 -18 2.47 -13
Net Cash From Continuing Operating Activities		 -25 7.50 1.37 16 -26 5.27 -13 5.00 -18 2.47 -13
Net Income / (Loss) Continuing Operations		 -13 -8.49 -9.49 -21 46 -29 -188 -13 -13 -11 -4.41
Consolidated Net Income / (Loss)		 -13 -8.49 -9.49 -21 46 -29 -188 -13 -13 -11 -4.41
Depreciation Expense		 7.66 7.82 7.84 7.56 6.69 6.69 7.52 6.82 6.79 6.86 6.32
Non-Cash Adjustments To Reconcile Net Income		 3.89 6.02 2.62 16 -45 3.25 161 2.30 4.19 3.34 3.15
Changes in Operating Assets and Liabilities, net		 -23 2.14 0.40 14 -34 24 6.72 9.33 -16 3.01 -18
Net Cash From Investing Activities		 -3.58 -2.50 -2.15 -1.53 98 -1.79 29 -2.34 -2.41 -1.96 -3.19
Net Cash From Continuing Investing Activities		 -3.58 -2.50 -2.15 -1.53 98 -1.79 29 -2.34 -2.41 -1.96 -3.19
Purchase of Property, Plant & Equipment		 -3.04 -2.50 -2.15 3.87 -1.56 -1.79 -1.85 2.68 -2.41 -1.96 -3.19
Net Cash From Financing Activities		 24 0.10 0.94 - -60 -0.35 0.69 -5.00 -0.51 -1.12 7.15
Net Cash From Continuing Financing Activities		 24 0.10 0.94 - -60 -0.35 0.69 -5.00 -0.51 -1.12 7.15
Issuance of Common Equity		 0.08 0.15 0.94 - 0.41 -0.35 0.69 - 0.04 -0.01 0.90
Other Financing Activities, net		 0.00 - - 1.17 -10 - - -4.25 0.00 - -0.06
Effect of Exchange Rate Changes		 -0.32 0.19 0.09 0.08 0.01 0.19 -0.02 -0.06 0.12 -0.31 -0.13

Annual Balance Sheets for AngioDynamics

This table presents AngioDynamics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 5/31/2022 5/31/2023 5/31/2024
Total Assets		 553 533 318
Total Current Assets		 143 164 193
Cash & Equivalents		 29 45 76
Accounts Receivable		 52 53 44
Inventories, net		 51 55 61
Prepaid Expenses		 11 4.62 13
Other Current Assets		 - - 0.00
Plant, Property, & Equipment, net		 45 44 36
Total Noncurrent Assets		 364 325 89
Intangible Assets		 152 111 77
Other Noncurrent Operating Assets		 11 11 11
Total Liabilities & Shareholders' Equity		 553 533 318
Total Liabilities		 128 154 112
Total Current Liabilities		 74 84 91
Short-Term Debt		 8.78 15 4.73
Accounts Payable		 28 40 38
Accrued Expenses		 35 27 41
Other Current Liabilities		 2.65 2.00 7.58
Total Noncurrent Liabilities		 54 71 21
Noncurrent Deferred & Payable Income Tax Liabilities		 16 13 4.85
Other Noncurrent Operating Liabilities		 13 7.89 16
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 424 378 206
Total Preferred & Common Equity		 424 378 206
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 424 378 206
Common Stock		 587 600 611
Retained Earnings		 -158 -211 -395
Treasury Stock		 -5.71 -5.71 -5.71
Accumulated Other Comprehensive Income / (Loss)		 1.36 -4.72 -4.37

Quarterly Balance Sheets for AngioDynamics

This table presents AngioDynamics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 8/31/2022 11/30/2022 2/28/2023 8/31/2023 11/30/2023 2/29/2024 8/31/2024 11/30/2024 2/28/2025
Total Assets		 558 558 543 494 500 325 294 292 285
Total Current Assets		 151 159 153 175 185 197 173 175 172
Cash & Equivalents		 25 30 30 58 61 78 55 54 45
Accounts Receivable		 54 53 51 50 52 49 40 43 43
Inventories, net		 58 63 64 60 64 58 65 66 63
Prepaid Expenses		 16 13 8.04 8.16 8.72 11 13 12 15
Other Current Assets		 - - - - - - - - 5.50
Plant, Property, & Equipment, net		 46 46 46 43 43 37 34 33 33
Total Noncurrent Assets		 360 353 345 275 272 91 87 83 81
Intangible Assets		 148 142 134 107 104 82 76 73 71
Other Noncurrent Operating Assets		 11 11 11 9.43 8.48 9.33 11 10 9.68
Total Liabilities & Shareholders' Equity		 558 558 543 494 500 325 294 292 285
Total Liabilities		 144 150 145 66 98 106 97 105 100
Total Current Liabilities		 66 74 70 57 78 86 77 89 78
Short-Term Debt		 8.89 9.76 9.88 4.73 9.39 9.50 4.80 4.96 5.00
Accounts Payable		 29 35 36 25 38 35 31 35 30
Accrued Expenses		 26 27 22 26 29 31 34 40 37
Other Current Liabilities		 2.68 2.59 2.38 1.84 1.76 10 6.52 8.97 5.76
Total Noncurrent Liabilities		 77 77 76 8.69 20 20 20 16 22
Noncurrent Deferred & Payable Income Tax Liabilities		 15 14 13 1.28 18 5.92 4.63 4.33 4.20
Other Noncurrent Operating Liabilities		 12 13 12 7.41 2.60 14 16 12 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 414 408 398 428 401 219 197 187 186
Total Preferred & Common Equity		 414 408 398 428 401 219 197 187 186
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 414 408 398 428 401 219 197 187 186
Common Stock		 590 594 597 604 606 609 614 617 620
Retained Earnings		 -171 -180 -189 -165 -194 -382 -408 -419 -423
Treasury Stock		 -5.71 -5.71 -5.71 -5.71 -5.71 -5.71 -6.27 -7.38 -7.38
Accumulated Other Comprehensive Income / (Loss)		 0.81 -0.29 -3.85 -5.65 -4.71 -2.81 -3.27 -3.75 -3.53

Annual Metrics and Ratios for AngioDynamics

This table displays calculated financial ratios and metrics derived from AngioDynamics' official financial filings.

Metric 2022 2023 2024
Period end date 5/31/2022 5/31/2023 5/31/2024
Growth Metrics		 - - -
Revenue Growth		 8.66% 7.13% -10.28%
EBITDA Growth		 100.95% -23,806.82% -693.50%
EBIT Growth		 16.85% -76.81% -273.54%
NOPAT Growth		 19.31% -79.77% -275.99%
Net Income Growth		 15.85% -97.54% -251.53%
EPS Growth		 17.07% -95.59% -245.11%
Operating Cash Flow Growth		 -129.86% 101.08% -36,200.00%
Free Cash Flow Firm Growth		 -9.68% 218.62% 75.96%
Invested Capital Growth		 4.41% -18.86% -61.47%
Revenue Q/Q Growth		 3.32% 1.22% -6.20%
EBITDA Q/Q Growth		 100.57% -229.89% 3.22%
EBIT Q/Q Growth		 32.98% -38.67% 3.14%
NOPAT Q/Q Growth		 34.79% -39.30% 3.21%
Net Income Q/Q Growth		 33.21% -40.82% 4.17%
EPS Q/Q Growth		 33.98% -41.49% 4.18%
Operating Cash Flow Q/Q Growth		 -102.36% 101.07% -63.66%
Free Cash Flow Firm Q/Q Growth		 -23.25% 303.99% -42.53%
Invested Capital Q/Q Growth		 -0.31% -18.44% -10.34%
Profitability Metrics		 - - -
Gross Margin		 52.41% 51.44% 50.90%
EBITDA Margin		 0.03% -6.16% -54.47%
Operating Margin		 -9.00% -15.11% -63.32%
EBIT Margin		 -9.25% -15.27% -63.59%
Profit (Net Income) Margin		 -8.40% -15.48% -60.66%
Tax Burden Percent		 88.64% 96.34% 96.20%
Interest Burden Percent		 102.35% 105.22% 99.16%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -4.74% -9.21% -55.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 52.30% 124.30% 42.32%
Return on Net Nonoperating Assets (RNNOA)		 -1.40% -3.85% -7.33%
Return on Equity (ROE)		 -6.15% -13.07% -63.15%
Cash Return on Invested Capital (CROIC)		 -9.06% 11.61% 32.93%
Operating Return on Assets (OROA)		 -5.25% -9.53% -45.45%
Return on Assets (ROA)		 -4.77% -9.66% -43.36%
Return on Common Equity (ROCE)		 -6.15% -13.07% -63.15%
Return on Equity Simple (ROE_SIMPLE)		 -6.25% -13.86% -89.67%
Net Operating Profit after Tax (NOPAT)		 -20 -36 -135
NOPAT Margin		 -6.30% -10.58% -44.32%
Net Nonoperating Expense Percent (NNEP)		 -57.04% -133.51% -98.13%
Cost of Revenue to Revenue		 47.59% 48.56% 49.10%
SG&A Expenses to Revenue		 12.16% 11.81% 13.54%
R&D to Revenue		 9.72% 8.82% 10.37%
Operating Expenses to Revenue		 61.41% 66.55% 114.22%
Earnings before Interest and Taxes (EBIT)		 -29 -52 -193
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.09 -21 -166
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.79 0.98 1.23
Price to Tangible Book Value (P/TBV)		 10.71 3.44 1.97
Price to Revenue (P/Rev)		 2.41 1.10 0.83
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.78 1.12 1.35
Enterprise Value to Revenue (EV/Rev)		 2.42 1.15 0.60
Enterprise Value to EBITDA (EV/EBITDA)		 8,706.95 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 5,014.56 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 8.66 2.28
Leverage & Solvency		 - - -
Debt to Equity		 0.08 0.17 0.02
Long-Term Debt to Equity		 0.06 0.13 0.00
Financial Leverage		 -0.03 -0.03 -0.17
Leverage Ratio		 1.29 1.35 1.46
Compound Leverage Factor		 1.32 1.42 1.44
Debt to Total Capital		 7.37% 14.58% 2.25%
Short-Term Debt to Total Capital		 1.92% 3.33% 2.25%
Long-Term Debt to Total Capital		 5.46% 11.25% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 92.63% 85.42% 97.75%
Debt to EBITDA		 383.90 -3.10 -0.03
Net Debt to EBITDA		 56.34 -0.96 0.43
Long-Term Debt to EBITDA		 284.09 -2.39 0.00
Debt to NOPAT		 -1.70 -1.80 -0.04
Net Debt to NOPAT		 -0.25 -0.56 0.53
Long-Term Debt to NOPAT		 -1.25 -1.39 0.00
Altman Z-Score		 3.71 1.38 -1.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 1.93 1.95 2.12
Quick Ratio		 1.09 1.16 1.31
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -38 45 79
Operating Cash Flow to CapEx		 -167.42% 2.05% -1,118.27%
Free Cash Flow to Firm to Interest Expense		 -55.35 16.72 0.00
Operating Cash Flow to Interest Expense		 -10.46 0.03 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -16.70 -1.38 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.57 0.62 0.71
Accounts Receivable Turnover		 7.21 6.44 6.30
Inventory Turnover		 3.01 3.08 2.57
Fixed Asset Turnover		 7.71 7.58 7.59
Accounts Payable Turnover		 6.31 4.80 3.82
Days Sales Outstanding (DSO)		 50.62 56.64 57.91
Days Inventory Outstanding (DIO)		 121.28 118.39 141.80
Days Payable Outstanding (DPO)		 57.82 75.98 95.64
Cash Conversion Cycle (CCC)		 114.08 99.04 104.07
Capital & Investment Metrics		 - - -
Invested Capital		 429 348 134
Invested Capital Turnover		 0.75 0.87 1.26
Increase / (Decrease) in Invested Capital		 18 -81 -214
Enterprise Value (EV)		 766 391 181
Market Capitalization		 761 371 253
Book Value per Share		 $10.95 $9.64 $5.13
Tangible Book Value per Share		 $1.83 $2.75 $3.20
Total Capital		 458 443 210
Total Debt		 34 65 4.73
Total Long-Term Debt		 25 50 0.00
Net Debt		 4.96 20 -71
Capital Expenditures (CapEx)		 4.30 3.81 2.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 49 50 31
Debt-free Net Working Capital (DFNWC)		 78 94 107
Net Working Capital (NWC)		 69 80 102
Net Nonoperating Expense (NNE)		 6.62 17 50
Net Nonoperating Obligations (NNO)		 4.96 -30 -71
Total Depreciation and Amortization (D&A)		 29 31 28
Debt-free, Cash-free Net Working Capital to Revenue		 15.49% 14.72% 10.12%
Debt-free Net Working Capital to Revenue		 24.60% 27.89% 35.15%
Net Working Capital to Revenue		 21.83% 23.53% 33.59%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($0.68) ($1.33) ($4.59)
Adjusted Weighted Average Basic Shares Outstanding		 39.01M 39.48M 40.18M
Adjusted Diluted Earnings per Share		 ($0.68) ($1.33) ($4.59)
Adjusted Weighted Average Diluted Shares Outstanding		 39.01M 39.48M 40.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.97M 39.67M 40.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -15 -24
Normalized NOPAT Margin		 -4.30% -4.34% -7.89%
Pre Tax Income Margin		 -9.47% -16.07% -63.06%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -42.53 -19.15 0.00
NOPAT to Interest Expense		 -28.97 -13.26 0.00
EBIT Less CapEx to Interest Expense		 -48.78 -20.56 0.00
NOPAT Less CapEx to Interest Expense		 -35.21 -14.67 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for AngioDynamics

This table displays calculated financial ratios and metrics derived from AngioDynamics' official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 8/31/2022 11/30/2022 2/28/2023 5/31/2023 8/31/2023 11/30/2023 2/29/2024 5/31/2024 8/31/2024 11/30/2024 2/28/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 5.93% 9.13% 9.11% 4.69% -3.51% -7.44% -6.85% -22.06% -14.22% -7.88% -4.23%
EBITDA Growth		 -299.73% 61.06% -159.82% -1,285.41% 812.35% -1,077.96% -17,570.83% 41.14% -115.66% 34.76% 100.92%
EBIT Growth		 -59.44% 3.71% -59.89% -220.75% 357.81% -57.19% -2,141.64% 29.84% -138.20% 15.74% 97.73%
NOPAT Growth		 -64.21% 6.50% -68.61% -225.73% 595.20% -61.68% -2,138.98% 30.66% -119.89% 15.44% 95.01%
Net Income Growth		 -86.52% -1.62% -91.31% -242.60% 452.85% -242.31% -1,879.29% 37.35% -127.89% 63.03% 97.65%
EPS Growth		 -83.33% 0.00% -84.62% -243.75% 448.48% -242.86% -1,845.83% 36.36% -126.96% 63.89% 97.64%
Operating Cash Flow Growth		 -177.91% 286.35% 115.58% 86.38% -4.66% -29.78% -1,014.31% -68.65% 29.52% -53.04% -5.05%
Free Cash Flow Firm Growth		 -300.29% -382.74% 33.80% 393.49% 472.90% 488.72% 5,241.05% 207.28% 83.86% 159.42% -102.43%
Invested Capital Growth		 5.33% 3.45% -0.83% -18.86% -16.34% -20.09% -64.95% -61.47% -60.96% -60.64% -2.43%
Revenue Q/Q Growth		 -6.28% 4.77% -5.52% 12.84% -13.61% 0.50% -4.92% -5.59% -4.92% 7.93% -1.15%
EBITDA Q/Q Growth		 -614.24% 90.56% -98.54% -1,130.00% 409.02% -115.61% -2,878.38% 95.90% 17.81% 34.95% 142.07%
EBIT Q/Q Growth		 -106.18% 37.91% -6.70% -134.81% 265.72% -137.86% -1,421.70% 92.65% 9.77% 16.49% 59.00%
NOPAT Q/Q Growth		 -107.93% 38.99% -10.02% -133.39% 416.10% -119.92% -1,423.60% 92.77% 9.35% 15.30% 10.10%
Net Income Q/Q Growth		 -107.53% 34.74% -11.77% -126.33% 313.74% -163.31% -546.30% 92.84% 4.84% 16.10% 58.96%
EPS Q/Q Growth		 -106.25% 36.36% -14.29% -129.17% 309.09% -162.61% -548.61% 92.51% 11.43% 16.13% 57.69%
Operating Cash Flow Q/Q Growth		 -389.08% 130.31% -81.73% 1,064.53% -262.34% 120.33% -337.87% 139.93% -464.99% 113.55% -632.11%
Free Cash Flow Firm Q/Q Growth		 -41.41% 36.69% 86.79% 2,582.18% 79.67% -34.00% 74.66% 48.36% 7.51% -6.88% -101.64%
Invested Capital Q/Q Growth		 4.36% -2.35% -2.38% -18.44% 7.60% -6.73% -57.18% -10.34% 9.03% -5.97% 6.15%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 51.88% 52.77% 50.18% 50.90% 50.92% 50.92% 47.70% 54.26% 54.41% 54.78% 53.97%
EBITDA Margin		 -7.13% -0.64% -1.35% -14.72% 52.66% -8.18% -256.19% -11.12% -9.61% -5.79% 2.47%
Operating Margin		 -16.31% -9.50% -11.06% -22.88% 44.52% -16.59% -265.88% -20.36% -19.41% -15.23% -13.85%
EBIT Margin		 -16.53% -9.79% -11.06% -23.02% 44.16% -16.63% -266.20% -20.72% -19.66% -15.21% -6.31%
Profit (Net Income) Margin		 -15.95% -9.93% -11.75% -23.57% 58.32% -36.74% -249.71% -18.95% -18.96% -14.74% -6.12%
Tax Burden Percent		 93.84% 93.76% 98.15% 98.18% 131.62% 230.21% 93.99% 95.11% 101.05% 98.99% 99.95%
Interest Burden Percent		 102.83% 108.18% 108.24% 104.30% 100.34% 95.94% 99.80% 96.15% 95.43% 97.89% 97.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% -31.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -8.39% -5.07% -6.04% -13.95% 47.83% -9.72% -209.03% -17.94% -15.26% -12.53% -18.57%
ROIC Less NNEP Spread (ROIC-NNEP)		 -39.61% -32.56% -27.13% 41.34% 50.20% 172.43% 33.79% -11.35% -8.21% -6.63% -23.31%
Return on Net Nonoperating Assets (RNNOA)		 -1.10% -0.79% -1.01% -1.28% -1.12% -4.65% -2.16% 1.97% 1.36% 1.13% 6.26%
Return on Equity (ROE)		 -9.49% -5.86% -7.05% -15.23% 46.71% -14.37% -211.19% -15.98% -13.90% -11.40% -12.31%
Cash Return on Invested Capital (CROIC)		 -10.59% -8.77% -5.16% 11.61% 17.31% 20.94% 47.94% 32.93% 23.08% 18.51% -20.55%
Operating Return on Assets (OROA)		 -9.52% -5.78% -6.82% -14.37% 28.21% -10.36% -198.81% -14.81% -14.62% -11.02% -5.86%
Return on Assets (ROA)		 -9.19% -5.86% -7.24% -14.71% 37.25% -22.89% -186.49% -13.54% -14.10% -10.68% -5.68%
Return on Common Equity (ROCE)		 -9.49% -5.86% -7.05% -15.23% 46.71% -14.37% -211.19% -15.98% -13.90% -11.40% -12.31%
Return on Equity Simple (ROE_SIMPLE)		 -7.87% -8.02% -9.37% 0.00% 1.51% -3.52% -87.96% 0.00% -123.63% -120.32% -22.27%
Net Operating Profit after Tax (NOPAT)		 -9.31 -5.68 -6.25 -15 46 -9.18 -140 -10 -9.17 -7.77 -6.98
NOPAT Margin		 -11.42% -6.65% -7.74% -16.02% 58.60% -11.61% -186.12% -14.25% -13.58% -10.66% -9.70%
Net Nonoperating Expense Percent (NNEP)		 31.23% 27.49% 21.09% -55.29% -2.38% -182.16% -242.82% -6.59% -7.04% -5.91% 4.74%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -2.24% -61.32% - - -4.05% -3.66%
Cost of Revenue to Revenue		 48.12% 47.23% 49.82% 49.10% 49.08% 49.08% 52.30% 45.74% 45.59% 45.22% 46.03%
SG&A Expenses to Revenue		 12.39% 12.68% 10.95% 11.23% 13.80% 11.75% 14.07% 14.71% 16.26% 14.26% 14.57%
R&D to Revenue		 10.22% 8.00% 8.49% 8.63% 10.09% 10.95% 10.89% 9.47% 9.31% 8.83% 9.60%
Operating Expenses to Revenue		 68.20% 62.27% 61.24% 73.78% 6.39% 67.51% 313.58% 74.62% 73.82% 70.01% 67.82%
Earnings before Interest and Taxes (EBIT)		 -13 -8.37 -8.93 -21 35 -13 -200 -15 -13 -11 -4.54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.82 -0.55 -1.09 -13 41 -6.47 -193 -7.89 -6.49 -4.22 1.78
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.08 1.24 1.22 0.98 0.74 0.65 1.00 1.23 1.53 1.51 2.02
Price to Tangible Book Value (P/TBV)		 13.27 7.76 7.61 3.44 1.97 1.88 1.60 1.97 2.49 2.48 3.27
Price to Revenue (P/Rev)		 2.69 1.54 1.45 1.10 0.95 0.79 0.68 0.83 1.03 0.98 1.33
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 49.42 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 2.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.00 1.23 1.20 1.12 0.71 0.60 1.00 1.35 1.71 1.69 2.30
Enterprise Value to Revenue (EV/Rev)		 2.80 1.63 1.54 1.15 0.79 0.63 0.46 0.60 0.85 0.81 1.19
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 10.07 10.20 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 5,014.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 8.66 3.73 2.53 1.08 2.28 4.16 5.15 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.14 0.15 0.15 0.17 0.01 0.02 0.04 0.02 0.02 0.03 0.03
Long-Term Debt to Equity		 0.12 0.12 0.13 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.03 0.02 0.04 -0.03 -0.02 -0.03 -0.06 -0.17 -0.17 -0.17 -0.27
Leverage Ratio		 1.31 1.32 1.31 1.35 1.25 1.31 1.41 1.46 1.26 1.35 1.51
Compound Leverage Factor		 1.35 1.43 1.42 1.41 1.25 1.25 1.41 1.40 1.20 1.32 1.46
Debt to Total Capital		 12.42% 12.74% 13.05% 14.58% 1.09% 2.29% 4.16% 2.25% 2.39% 2.59% 2.62%
Short-Term Debt to Total Capital		 1.88% 2.09% 2.16% 3.33% 1.09% 2.29% 4.16% 2.25% 2.39% 2.59% 2.62%
Long-Term Debt to Total Capital		 10.53% 10.65% 10.89% 11.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 87.58% 87.26% 86.95% 85.42% 98.91% 97.71% 95.84% 97.75% 97.61% 97.41% 97.38%
Debt to EBITDA		 -13.74 -17.45 -9.44 -3.10 0.18 0.46 -0.06 -0.03 -0.02 -0.02 -0.30
Net Debt to EBITDA		 -7.99 -8.70 -4.68 -0.96 -2.00 -2.52 0.40 0.43 0.24 0.23 2.36
Long-Term Debt to EBITDA		 -11.65 -14.59 -7.88 -2.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.49 -2.57 -2.32 -1.80 -2.37 -1.71 -0.07 -0.04 -0.03 -0.03 -0.15
Net Debt to NOPAT		 -1.45 -1.28 -1.15 -0.56 26.49 9.37 0.50 0.53 0.30 0.29 1.17
Long-Term Debt to NOPAT		 -2.11 -2.15 -1.94 -1.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.85 2.29 2.26 1.57 3.62 1.87 -1.03 0.80 1.15 0.82 1.53
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.28 2.16 2.19 1.95 3.05 2.38 2.29 2.12 2.25 1.98 2.21
Quick Ratio		 1.18 1.12 1.16 1.16 1.87 1.44 1.49 1.31 1.23 1.10 1.13
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -32 -20 -2.68 66 119 79 138 204 219 204 -3.34
Operating Cash Flow to CapEx		 -815.05% 300.44% 63.84% 0.00% -1,662.32% 293.70% -678.55% 0.00% -758.96% 126.11% -412.64%
Free Cash Flow to Firm to Interest Expense		 -83.99 -29.62 -3.64 73.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -64.95 10.96 1.86 17.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -72.92 7.31 -1.05 22.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.58 0.59 0.62 0.62 0.64 0.62 0.75 0.71 0.74 0.72 0.93
Accounts Receivable Turnover		 7.21 7.20 7.22 6.44 6.50 6.31 6.46 6.30 6.55 6.05 6.10
Inventory Turnover		 2.86 2.79 2.87 3.08 2.79 2.55 2.66 2.57 2.27 2.08 2.13
Fixed Asset Turnover		 7.35 7.37 7.51 7.58 7.50 7.45 7.85 7.59 7.53 7.59 8.14
Accounts Payable Turnover		 5.89 5.28 5.61 4.80 6.06 4.49 4.56 3.82 5.04 3.74 3.95
Days Sales Outstanding (DSO)		 50.63 50.67 50.55 56.64 56.15 57.85 56.53 57.91 55.69 60.36 59.87
Days Inventory Outstanding (DIO)		 127.62 130.68 127.00 118.39 130.93 143.24 137.44 141.80 160.95 175.33 171.01
Days Payable Outstanding (DPO)		 62.01 69.10 65.07 75.98 60.20 81.31 79.97 95.64 72.40 97.51 92.32
Cash Conversion Cycle (CCC)		 116.25 112.26 112.47 99.04 126.87 119.78 114.00 104.07 144.24 138.18 138.55
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 448 438 427 348 375 350 150 134 146 138 146
Invested Capital Turnover		 0.73 0.76 0.78 0.87 0.82 0.84 1.12 1.26 1.12 1.18 1.92
Increase / (Decrease) in Invested Capital		 23 15 -3.57 -81 -73 -88 -277 -214 -229 -212 -3.64
Enterprise Value (EV)		 897 536 514 391 266 209 150 181 250 232 336
Market Capitalization		 863 506 484 371 319 260 219 253 300 282 376
Book Value per Share		 $10.62 $10.43 $10.16 $9.64 $10.78 $10.07 $5.49 $5.13 $4.88 $4.60 $4.59
Tangible Book Value per Share		 $1.67 $1.67 $1.63 $2.75 $4.09 $3.47 $3.44 $3.20 $3.00 $2.80 $2.84
Total Capital		 473 468 457 443 433 411 228 210 201 192 191
Total Debt		 59 60 60 65 4.73 9.39 9.50 4.73 4.80 4.96 5.00
Total Long-Term Debt		 50 50 50 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 34 30 30 20 -53 -52 -69 -71 -50 -49 -40
Capital Expenditures (CapEx)		 3.04 2.50 2.15 -3.87 1.56 1.79 1.85 -2.68 2.41 1.96 3.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 69 65 63 50 65 56 42 31 46 38 55
Debt-free Net Working Capital (DFNWC)		 94 95 93 94 123 117 121 107 101 92 99
Net Working Capital (NWC)		 85 85 83 80 118 107 111 102 96 87 94
Net Nonoperating Expense (NNE)		 3.69 2.81 3.24 6.88 0.22 20 48 3.33 3.63 2.97 -2.57
Net Nonoperating Obligations (NNO)		 34 30 30 -30 -53 -52 -69 -71 -50 -49 -40
Total Depreciation and Amortization (D&A)		 7.66 7.82 7.84 7.56 6.69 6.69 7.52 6.82 6.79 6.86 6.32
Debt-free, Cash-free Net Working Capital to Revenue		 21.61% 19.87% 18.74% 14.72% 19.40% 16.97% 12.99% 10.12% 15.61% 13.14% 19.25%
Debt-free Net Working Capital to Revenue		 29.26% 28.98% 27.73% 27.89% 36.54% 35.45% 37.20% 35.15% 34.40% 32.02% 35.05%
Net Working Capital to Revenue		 26.49% 26.00% 24.78% 23.53% 35.14% 32.60% 34.27% 33.59% 32.76% 30.28% 33.28%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.33) ($0.21) ($0.24) ($0.55) $1.15 ($0.72) ($4.67) ($0.35) ($0.31) ($0.26) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 39.30M 39.49M 39.51M 39.48M 39.84M 40.22M 40.23M 40.18M 40.65M 40.92M 40.85M
Adjusted Diluted Earnings per Share		 ($0.33) ($0.21) ($0.24) ($0.55) $1.15 ($0.72) ($4.67) ($0.35) ($0.31) ($0.26) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 39.30M 39.49M 39.51M 39.48M 39.97M 40.22M 40.23M 40.18M 40.65M 40.92M 40.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 39.11M 39.13M 39.24M 39.67M 39.85M 39.86M 40.05M 40.28M 40.63M 40.47M 40.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.40 -3.54 -3.89 -12 -6.72 -4.85 -8.20 -4.22 -6.15 -3.66 -4.68
Normalized NOPAT Margin		 -6.63% -4.14% -4.82% -13.23% -8.54% -6.14% -10.90% -5.95% -9.11% -5.02% -6.50%
Pre Tax Income Margin		 -16.99% -10.59% -11.97% -24.01% 44.31% -15.96% -265.68% -19.92% -18.77% -14.89% -6.12%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -35.37 -12.23 -12.13 -23.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -24.44 -8.30 -8.49 -16.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -43.34 -15.88 -15.05 -18.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -32.41 -11.95 -11.41 -11.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About AngioDynamics' Financials

When does AngioDynamics's fiscal year end?

According to the most recent income statement we have on file, AngioDynamics' financial year ends in May. Their financial year 2024 ended on May 31, 2024.

How has AngioDynamics' net income changed over the last 2 years?

AngioDynamics' net income appears to be on an upward trend, with a most recent value of -$184.35 million in 2024, rising from -$26.55 million in 2022. The previous period was -$52.44 million in 2023. Check out AngioDynamics' forecast to explore projected trends and price targets.

What is AngioDynamics's operating income?
AngioDynamics's total operating income in 2024 was -$192.44 million, based on the following breakdown:
  • Total Gross Profit: $154.70 million
  • Total Operating Expenses: $347.13 million
How has AngioDynamics revenue changed over the last 2 years?

Over the last 2 years, AngioDynamics' total revenue changed from $316.22 million in 2022 to $303.91 million in 2024, a change of -3.9%.

How much debt does AngioDynamics have?

AngioDynamics' total liabilities were at $112.09 million at the end of 2024, a 27.4% decrease from 2023, and a 12.6% decrease since 2022.

How much cash does AngioDynamics have?

In the past 2 years, AngioDynamics' cash and equivalents has ranged from $28.83 million in 2022 to $76.06 million in 2024, and is currently $76.06 million as of their latest financial filing in 2024.

How has AngioDynamics' book value per share changed over the last 2 years?

Over the last 2 years, AngioDynamics' book value per share changed from 10.95 in 2022 to 5.13 in 2024, a change of -53.1%.


Related Companies

This page (NASDAQ:ANGO) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored